Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 0.70 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | APEX1 | P27695 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781913 | 1.00 | TRPA1 (0.70) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2779873 | 0.88 | TRPA1 (0.82) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2780018 | 0.88 | TRPA1 (0.70) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2779875 | 0.88 | TRPA1 (0.82) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2780021 | 0.88 | TRPA1 (0.70) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16272332 | 0.87 | TRPA1 (0.65) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2779418 | 0.87 | TRPA1 (0.73) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2779414 | 0.87 | TRPA1 (0.73) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2780237 | 0.86 | TRPA1 (0.71) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2780239 | 0.86 | TRPA1 (0.71) | TRPA1TRPM8MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010071865-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2173167-A2 | TREATMENT OF NEUROPATHIC PAIN | Nuon Therapeutics, Inc. (US) | 2010-04-14 | — | — | EP | claimed |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) | 2010-02-18 | — | — | US | claimed |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM | 2009-12-17 | — | — | US | claimed |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | NUON THERAPEUTICS, INC. | 2009-08-06 | — | — | US | claimed |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS INC. | 2009-02-12 | — | — | US | claimed |
| WO-2009008997-A2 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| EP-1824469-A4 | A METHOD OF MODULATING B CELL FUNCTIONING | NUON THERAPEUTICS PTY LTD (AU) | 2008-07-30 | — | — | EP | claimed |
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | EBERHARD-KARLS-UNIVERSITAT TUBINGEN (DE) | 2008-05-01 | — | — | US | claimed |
| EP-1845967-A4 | A METHOD OF MODULATING T CELL FUNCTIONING | UNIV LELAND STANFORD JUNIOR (US) | 2008-03-05 | — | — | EP | claimed |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2008-01-10 | — | — | US | claimed |
| EP-1845967-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | The Board of Trustees of Leland Stanford Junior University (US) | 2007-10-24 | — | — | EP | claimed |
| EP-1824469-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | Angiogen Pharmaceuticals Pty. Ltd (AU) | 2007-08-29 | — | — | EP | claimed |
| WO-2006076580-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-07-20 | — | — | WO | claimed |
| WO-2006053390-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) | 2006-05-26 | — | — | WO | claimed |
| EP-2253313-A1 | Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2006076580-A2 | A METHOD OF MODULATING T CELL FUNCTIONING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006053390-A1 | A METHOD OF MODULATING B CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY. LTD. (AU) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | NLN, GAP43, CYBB | TRPA1 2236/4885TRPM8 1771/4885MEN1 3828/4885 |
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | PTGS2, PTGES2, PTGES | TRPA1 406/4885TRPM8 2868/4885MEN1 4678/4885 |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | XDH, SLC10A1, SLC10A6 | TRPA1 4098/4885TRPM8 2370/4885MEN1 1944/4885 |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | IFNG, CD4, IDO1 | TRPA1 901/4885TRPM8 1509/4885MEN1 3959/4885 |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | OPRL1, OPRK1, ACHE | TRPA1 72/4885TRPM8 946/4885MEN1 3723/4885 |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | OPRL1, GAP43, AANAT | TRPA1 15/4885TRPM8 353/4885MEN1 3473/4885 |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | KYNU, IDO1, IDO2 | TRPA1 1754/4885TRPM8 3913/4885MEN1 3204/4885 |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | NLN, GAP43, CYBB | TRPA1 2236/4885TRPM8 1771/4885MEN1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.